{"entity":{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","aka":[],"tldr":"Seven in ten cancer deaths are in poorer countries, yet almost all trials happen in rich ones. Funders would commit a share of money for trials designed and led where the burden is.","summary":"The largest cancer research funders commit a fixed fraction (say 15%) of their trials budget to studies whose principal investigator and majority of sites are in low- and middle-income countries, targeting cancers and questions that matter there: cervical cancer treatment with limited radiotherapy, oesophageal squamous cell carcinoma, hepatocellular carcinoma from hepatitis B, hypofractionation and shorter regimens, low-cost generics. Precedents include Tata Memorial's trials that changed global practice on low-dose immunotherapy and neoadjuvant chemotherapy in head and neck cancer at a fraction of Western trial costs.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Funding follows fashion, not burden): Carter & Nguyen, A comparison of cancer burden and research spending (BMC Cancer 2012)","url":"https://doi.org/10.1186/1471-2407-12-526"}],"tags":[],"related":["idea-fund-global-cancer-fund","idea-fund-lmic-radiotherapy-finance"],"cancers":["cervical","esophageal","hcc","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","einstein-sao-paulo","sysucc"],"pathways":[],"terms":[],"trials":[],"people":["badwe-rajendra","gupta-sudeep","barrios-carlos"],"bottlenecks":["b-funding-allocation","b-global-access","b-trial-diversity"],"keyPapers":["paper-sun-bmc-cancer"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A burden-matched commitment produces at least ten practice-changing phase 3 results relevant to LMIC settings within a decade at a per-patient cost under a third of comparable high-income trials, and doubles the LMIC share of registered interventional oncology trials.","rationale":"Trials in India, Brazil and China have shown that large, pragmatic, low-cost phase 3s are feasible and change guidelines; the limiting factor is core funding for trial units rather than science. Results generalise upward more often than down: hypofractionation and de-escalation findings from LMIC trials have been adopted in rich countries.","test":"Two funders pool a pilot fund of tens of millions, award competitively to LMIC-led trial units, and audit after five years for trials completed, guideline citations and cost per patient compared with the funders' other trials.","maturity":"speculative","actor":"philanthropy","cost":"large","horizonYears":6},"route":"/ideas/idea-fund-lmic-burden-match/","neighbours":{"idea":[{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/"},{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"institution":[{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/"},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/"},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"person":[{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/"},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/"},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"paper":[{"id":"paper-sun-bmc-cancer","kind":"paper","name":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials","route":"/key-papers/paper-sun-bmc-cancer/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}